Pernix Therapeutics (PTX) Reports Q4 GAAP EPS of 7c
Tweet
Share
E-mailGet Alerts PTX Hot Sheet
Join SI Premium – FREE
Pernix Therapeutics Holdings (NYSE: PTX) reported Q4 GAAP EPS of $0.07, so may not compare to the analyst estimate of $0.14. Revenue for the quarter came in at $12.2 million versus the consensus estimate of $13.08 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance
- Target (TGT) Tops Q2 EPS by $1.78, Beats on Revenue; Offers FY27 EPS Guidance
- Walmart shares fall despite earnings beat
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
